Health Care·Pharmaceuticals·$2.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.19 | N/A | -20.61% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.19 | N/A | -20.61% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future growth driven by their product pipeline. They highlighted the strategic focus on upcoming launches.
Management noted the ongoing focus on pipeline development.
They emphasized the importance of upcoming product launches.
Despite missing EPS expectations, Supernus Pharmaceuticals saw a positive stock reaction, rising 3.13%. This could indicate investor confidence in the company's future growth potential, particularly with their focus on product development and upcoming launches. The lack of revenue data may leave some investors cautious, but the overall sentiment appears to be optimistic.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
JD COM INC Class A ADR
May 8, 2017